Skip to main content
AmigoFish

Why investors are taking another look at kidney disease

From BioSpace · · 18 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.

Host

Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace

Guests

Bruce Culleton (https://www.linkedin.com/in/bruce-culleton-424b827/), CEO, ProKidney

Demetri Maxim (https://www.linkedin.com/in/demetri-maxim/), CEO, Nephrogen

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Back to BioSpace · Report a problem